BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25275600)

  • 21. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action.
    Chen R; Tsai J; Thompson PA; Chen Y; Xiong P; Liu C; Burrows F; Sivina M; Burger JA; Keating MJ; Wierda WG; Plunkett W
    Blood Cancer J; 2021 Mar; 11(3):57. PubMed ID: 33714981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway.
    Lafarge ST; Johnston JB; Gibson SB; Marshall AJ
    Leuk Res; 2014 Jan; 38(1):109-15. PubMed ID: 23981382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
    Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression levels of Lyn, Syk, PLCγ2 and ERK in patients with chronic lymphocytic leukemia, and higher levels of Lyn are associated with a shorter treatment-free survival.
    Wang YH; Fan L; Wang L; Zhang R; Zou ZJ; Fang C; Zhang LN; Li JY; Xu W
    Leuk Lymphoma; 2013 Jun; 54(6):1165-70. PubMed ID: 23039362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL.
    Kaplan D; Meyerson HJ; Li X; Drasny C; Liu F; Costaldi M; Barr P; Lazarus HM
    Cytometry B Clin Cytom; 2010 Mar; 78(2):115-22. PubMed ID: 20014315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia.
    Chen L; Huynh L; Apgar J; Tang L; Rassenti L; Weiss A; Kipps TJ
    Blood; 2008 Mar; 111(5):2685-92. PubMed ID: 18048647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the mRNA expression profile of B-cell receptor components in normal CD5-high B-lymphocytes and chronic lymphocytic leukemia: a key role of ZAP70.
    Gladkikh AA; Potashnikova DM; Tatarskiy V; Yastrebova M; Khamidullina A; Barteneva N; Vorobjev I
    Cancer Med; 2017 Dec; 6(12):2984-2997. PubMed ID: 29125235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients.
    Colado A; Almejún MB; Podaza E; Risnik D; Stanganelli C; Elías EE; Dos Santos P; Slavutsky I; Fernández Grecco H; Cabrejo M; Bezares RF; Giordano M; Gamberale R; Borge M
    Cancer Immunol Immunother; 2017 Apr; 66(4):461-473. PubMed ID: 28011996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70.
    Secchiero P; di Iasio MG; Gonelli A; Barbarotto E; Melloni E; Tiribelli M; Chiaruttini C; Zauli G
    J Cell Physiol; 2007 Oct; 213(1):229-36. PubMed ID: 17476690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
    Robak T; Robak P
    Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia.
    Le Roy C; Deglesne PA; Chevallier N; Beitar T; Eclache V; Quettier M; Boubaya M; Letestu R; Lévy V; Ajchenbaum-Cymbalista F; Varin-Blank N
    Blood; 2012 Jul; 120(2):356-65. PubMed ID: 22613791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
    Hoellenriegel J; Coffey GP; Sinha U; Pandey A; Sivina M; Ferrajoli A; Ravandi F; Wierda WG; O'Brien S; Keating MJ; Burger JA
    Leukemia; 2012 Jul; 26(7):1576-83. PubMed ID: 22362000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.
    Petlickovski A; Laurenti L; Li X; Marietti S; Chiusolo P; Sica S; Leone G; Efremov DG
    Blood; 2005 Jun; 105(12):4820-7. PubMed ID: 15728130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.
    Cosimo E; Tarafdar A; Moles MW; Holroyd AK; Malik N; Catherwood MA; Hay J; Dunn KM; Macdonald AM; Guichard SM; O'Rourke D; Leach MT; Sansom OJ; Cosulich SC; McCaig AM; Michie AM
    Clin Cancer Res; 2019 Mar; 25(5):1574-1587. PubMed ID: 30559170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms determining a differential threshold for sensing Src family kinase activity by B and T cell antigen receptors.
    Borna S; Fabisik M; Ilievova K; Dvoracek T; Brdicka T
    J Biol Chem; 2020 Sep; 295(37):12935-12945. PubMed ID: 32665402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lymphocytic leukemia.
    Chen J; Sathiaseelan V; Moore A; Tan S; Chilamakuri CSR; Roamio Franklin VN; Shahsavari A; Jakwerth CA; Hake SB; Warren AJ; Mohorianu I; D'Santos C; Ringshausen I
    Blood; 2021 Jul; 137(26):3629-3640. PubMed ID: 33619528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia.
    Vangapandu HV; Havranek O; Ayres ML; Kaipparettu BA; Balakrishnan K; Wierda WG; Keating MJ; Davis RE; Stellrecht CM; Gandhi V
    Mol Cancer Res; 2017 Dec; 15(12):1692-1703. PubMed ID: 28835371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.
    Longo PG; Laurenti L; Gobessi S; Sica S; Leone G; Efremov DG
    Blood; 2008 Jan; 111(2):846-55. PubMed ID: 17928528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the B cell receptor pathway in chronic lymphocytic leukemia.
    Davids MS; Brown JR
    Leuk Lymphoma; 2012 Dec; 53(12):2362-70. PubMed ID: 22616724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.
    Balakrishnan K; Peluso M; Fu M; Rosin NY; Burger JA; Wierda WG; Keating MJ; Faia K; O'Brien S; Kutok JL; Gandhi V
    Leukemia; 2015 Sep; 29(9):1811-22. PubMed ID: 25917267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.